Go to Page # Page of 16

Comparison of SurePath and GluCyte LBC Platforms.

 Reza Alaghehbandan MD
Description: The objective is to assess and compare the predictability of novel biomarkers, MCM/Top2A HPV E6E7 mRNA and HPV DNA in women with ASC-US technology in SurePath and Glucyte Cell solution liquid-based cytology(LBC) platforms.
Important Tags: HPV DNA
Views: 3490
Domain: Medical
Category: Biology
Contributing Organization: ESP-Pathology
 ‐ More of their Presentations
Comparison of SurePath and GluCyte LBC
platforms in detecting CIN2+ among ASCUS cytology patients using biomarkers
Reza Alaghehbandan, MD, MSc, FRCPC, FCAP

Department of Pathology, Royal Columbian Hospital (RCH)
Faculty of Medicine, University of British Columbia (UBC)
Vancouver, BC, Canada

I declare no conflicts of interest.

• Two commercially available LBC systems, ThinPrep (Hologic In ... See more

Recent Presentations

19 April, 2019

FDA Approach to the Opioids Crisis

Opioid Crisis is not one crisis, but multiple challenges to prescribers, patients & healthcare system. FDA is working in a prioritized way in multiple areas to confront opioid over

18 April, 2019
Ralph F. Hall
17 April, 2019